The resistance of melanoma to apoptosis, as well as its growth and metastasis capabilities, can be overcome by expression of a peptide derived from amino acid (aa) 51 to 100 of ATF2. Here we show that expression of ATF2 (51-100) in human melanoma cells reduced their growth in nude mice, which was additionally inhibited upon treatment with protein kinase inhibitors UCN-01 or SB203580. Injection of a fusion protein consisting of HIV-TAT and aa 51 to 100 of ATF2 into SW1 melanomas efficiently inhibits their growth and their metastasis up to complete regression. Additionally, expression of a 10aa peptide that corresponds to aa 51 to 60 of ATF2 sensitizes melanoma cells to spontaneous apoptosis, which coincides with activation of caspase 9 and poly(ADPribose) polymerase cleavage, and inhibit their growth in vivo. The 10aa peptide increases the association of c-Jun NH 2 -terminal kinase with c-Jun but not with ATF2, resulting in concomitant increase in TRE-mediated transcription. Our study points to mechanisms underlying the activities of the ATF2 peptide while highlighting its possible use in drug design.
INTRODUCTION
The notorious resistance of melanoma to treatment with its strong potential to metastasize represents the major clinical obstacle in the treatment of tumors of this type. A growing body of knowledge points to numerous changes in the apoptosis cascades that take place in human melanoma. The effects of such changes are to render such tumors insensitive to apoptosis after many treatments (reviewed in refs. 1, 2) . Among the changes identified is the activation of certain signaling cascades, including mitogen-activated protein kinase, as a result of an activating mutation within B-Raf and N-Ras (3, 4) , resulting in the constitutive activation of downstream effectors. Several transcription factors likely to serve as primary targets of altered signaling cascades, including ATF2, AP2, Jun, STAT3, and nuclear factor B (NF-B), have been implicated in melanoma development and progression (5) (6) (7) (8) (9) .
ATF2 is a member of the bZIP family of transcription factors that requires heterodimerization with other members of this family, including c-Jun, JunD, JunB, Fos, Fra1, ATFx, and ATFa (10, 11) , as well as with other regulatory components, including NF-B and retinoblastoma (12, 13) , to elicit its transcriptional activities. Also prerequisite is its phosphorylation by JNK and p38 (14, 15) . Inhibition of ATF2 activities results in sensitization of melanoma as well as breast cancer cells to apoptosis after treatment with radiomimetic or chemotherapeutic drugs that by themselves fail to affect these tumors (16) . Additionally, expression of a 50aa peptide obtained from the amino terminal domain of ATF2 suffices to inhibit ATF2 transcriptional activities and sensitize melanoma to treatment, as well as to inhibit tumor growth in vivo (17) . This region was shown to be important for the association of JNK and p38 3 (18) , which is prerequisite to their phosphorylation of ATF2 on aa 69 to 71; mutation within the residues required for JNK but not p38 association on ATF2 impairs the activities of the ATF2 peptide both in vitro and in vivo (18) . Here we show that a 10aa peptide that contains the JNK binding site on ATF2 increases JNK association with c-Jun, resulting in concomitant increase in spontaneous apoptosis and inhibition of tumorigenicity of melanoma in vivo.
MATERIALS AND METHODS
Cell Culture and Derivation of Stable Cell Line. Human melanoma LU1205 cells were maintained in MCDB153/L15 medium (4:1) supplemented with 5% fetal bovine serum, L-glutamine, and antibiotics. FEMX are late-phase melanoma-derived cells that were maintained in RPMI 1640 supplemented with 5% fetal bovine serum, L-glutamine, and antibiotics. The mouse melanoma cell line SW1 was maintained in DMEM supplemented with 10% fetal bovine serum; 293T human embryo kidney cells were grown in DMEM supplemented with 10% calf serum and antibiotics at 37°C with 5% CO 2 . SW1 clones that stably express the ATF2 peptides were selected in the presence of G418 (600 g/mL). Positive clones were selected after confirmation of expression by Western blot analysis, immunohistochemistry, or reverse transcription-PCR.
Constructs. The short ATF2 peptides were generated by introducing stop codons at the respective position into hemagglutinin (HA)-penetratin pcDNA3 ATF2 51 to 100aa vector (16) with the Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The 5xJun2-Luc and 5xTRE-Luc constructs have been described previously (16, 17) . DNA sequencing and reverse transcription-PCR were carried out in all of the cases to confirm the integrity of each construct as well as its expression levels. Amino acids 51 to 100 of ATF2 were cloned into the HIV-TAT construct (19) within the NcoI and XhoI sites. The fusion protein was expressed in the BL21 (DE3) pLysS (Novagen, Madison, WI) bacterial strain, and proteins were induced after the standard isopropyl-1-thio-␤-D-galactopyranoside protocol before being subjected to purification with the aid of nickel-nitrilo-triacetic acid beads. The retroviral vector used to express green fluorescent protein (GFP) in SW1 cells is a derivative of the Moloney Murine Leukemia virus vector pMMP412 into which an internal ribosome entry site-puromycin resistance cassette was inserted downstream of the GFP.
Transcription Analysis. Reporter constructs indicated in Results (0.3 g) were cotransfected with the respective expression vectors into melanoma cells (5 ϫ 10 5 ) with LipofectAMINE (Invitrogen, Carlsbad, CA). Luciferase activity was measured using the Luciferase assay system (Promega, Madison, WI).
Apoptosis Studies. Cells were analyzed to detect spontaneous (basal) or induced apoptosis [after treatment with the kinase inhibitor UCN-01 (kindly provided by National Cancer Institute repository) for 36 hours]. Apoptosis was measured by using fluorescence-activated cell sorter (8) to quantify the percentage of hypodiploid nuclei undergoing DNA fragmentation. Nucleation as a marker of apoptosis was monitored via 4Ј,6-diamidino-2-phenylindole staining of cells at indicated time points after their treatment. Caspase activity was monitored by immunoblots with antibodies to caspase 9 (Santa Cruz Biotechnology, Santa Cruz, CA). Poly(ADP-ribose) polymerase (PARP) cleavage was monitored by corresponding antibodies (PharMingen, San Diego, CA).
In Vitro Binding Assay. Flag JNK2 expressed in 293T cells extracted, immunopurified with anti-Flag antibody bound to protein G agarose beads were first incubated with 3 mg/mL of BSA in PBS for 2 hours, followed by incubation at 4°C for 2 hours with 35 S-labeled in vitro translated c-Jun or ATF2 (TNT-coupled reticulocyte lysate system, Promega) in the presence of wildtype or mutant peptide. Bead-bound material was subjected to three washes with 20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.5% NP40, 1 mmol/L NaVO 4 , and 1 mmol/L DTT supplemented with protease inhibitors. Reaction mixtures were then separated on SDS-PAGE and transferred onto a nitrocellulose membrane. Binding was detected by autoradiography and quantified with the aid of a phosphorimager. The wild-type and the mutant ATF2 51 to 60aa peptides were synthesized (Sigma Genosys, Woodland, TX) at a scale of 5 mg with Ͼ95% purity.
Tumor Growth in Vivo. LU1205, FEMX, and SW-1 cells that express control or ATF2 51-100 peptide were trypsinized, resuspended in PBS, and injected s.c. (1 ϫ 10 6 ) into 6-to 7-week-old mice in the lower flank. When the tumor reached the size of about 50 mm 3 , 10 mol/L of SB203580 was injected into four of the LU1205 tumors every 4 days during a 2-week period. For FEMX tumors, UCN-01 (5 mg/kg) was fed by gavage three times per week for a total of 2 weeks. Tumor growth was monitored every two days. SW-1 cells that express wild-type or mutant forms of the ATF2 peptide were trypsinized, resuspended in PBS, and injected subcutaneously in the lower flank (1 ϫ 10 4 ) of 6-to 7-week-old mice as described previously (17) . GFP-expressing SW1 tumors were monitored in vivo on shaved mice at the indicated time points with a light box illuminated by blue light fiber optics (Lightools Research, Encinitas, CA), and imaging was carried out with a digital camera (Nikon D100). Injection of HIV-TAT, control or fused with ATF2 peptide, was performed on 48-mm 3 size tumors at the indicated time points. Each injection was directed at multiple sites within the tumors. Tissue samples were fixed in formalin and embedded in paraffin. H&E terminal deoxynucleotidyl transferase (Tdt)-mediated nick-end labeling (TUNEL) staining was performed as described previously (16) .
The cDNA Microarray Hybridization. The 10k mouse Gem 2 gene set (Incyte Genomics Inc., Palo Alto, CA) was printed at the National Cancer Institute on poly-L-lysine-coated glass with a Biorobotics TASII arrayer (Cambridge, England). All protocols for manufacturing and hybridization of microarrays are posted on the National Cancer Institute web site (http:// nciarray.nci.nih.gov). Approximately 20 g of total RNA were used in the reverse transcription reaction to directly label the probe with Cy-5 dUTP or Cy-3 dUTP (Amersham, Piscataway, NJ). Hybridizations were performed at 65°C for 12 to 18 hours in a hybridization volume of 35 L. The hybridized arrays were scanned with an Axon GenePix 4000 scanner (Union City, CA), and fluorescence data were collected with the GenePix software.
Data Analysis. The normalization of the sample intensities and calculation of the calibrated fluorescence ratios after background subtraction were determined with the GenePix 4.0 software package (Axon Instrument, Union City, CA). Four independent array hybridizations were conducted for each sample. Spots that did not pass predefined criteria of minimum signal to noise were excluded. Filters were set to eliminate any spots for which the signals were Ͻ2-fold higher than the normalized background. Signals because of the presence of localized artifacts on the array image such as dust or lint were flagged as "bad" and excluded from the dataset. The ratio distribution extracted from each microarray image exhibited normal distribution, constant coefficient-ofvariation, and high positive signal (Fig. 5) . We used 2-fold above background as the intensity cutoff in all of the experiments. Thus, satisfying the statistical conditions required to determine the significance of ratio measurements by the confidence interval generated with web-based microarray analysis tools at mAdb. Under our experimental conditions, a 99% confidence interval defined ratios of 2 or larger or 0.5 and smaller as indicators of substantially different gene expression levels between two samples hybridized to the same array spot. We have used expression ratio calculations to determine whether gene expression differs substantially between the red and green channels. The distribution parameter can be estimated with a maximum likelihood method, and ratio calibration can be carried out by an iterative method. In our analyses, we have found that ratios of Ͼ2.0 are consistent on repeated hybridizations, although values as low as 1.5 were often found to be substantial after real-time PCR validation.
Higher order array analysis including gene clustering was performed with web-based tools available at the National Cancer Institute microarray web site (http://nciarray.nci.nih.gov). 51-100 reduced the growth rates of the two human melanoma tumors ( Fig. 1, A and B ). An additional decrease in growth of tumors that express ATF2 51-100 was found when they were treated with the pharmacological inhibitor of p38 or the chemotherapeutic drug UCN-01 ( Fig. 1, A and B) . TUNEL analysis revealed a marked increase in the degree of apoptosis in tumors expressing the ATF2 51-100 peptide on their exposure to additional treatment (Fig. 1C) . These results suggest that expression of the ATF2 51-100 peptide suffices to slow the growth rate and to sensitize human melanoma tumors to apoptosis following treatment.
RESULTS

Growth of Human Melanomas
Expression of a 50aa peptide that corresponds to aa 151 to 200 of the ATF2-transactivating domain relieves intramolecular inhibition, resulting in elevated ATF2 transcriptional activities. Expression of aa 151 to 200 of ATF2 in human melanoma cells increased their resistance to chemotherapeutic drugs and radiation, which is opposite to the effect of the ATF2 51-100 peptide (16) . Single injection of the LU1205 cells that constitutively express aa 151 to 200 of ATF2 into nude mice resulted in formation of Ͼ30 tumors within 6 weeks (data not shown), further illustrating the important role ATF2 plays in the promotion and growth of melanoma, thereby pointing to the need for inhibition of endogenous ATF2 function. 
Injection of HIV-TAT-ATF2
51-100 Inhibits Growth and Metastasis of SW1 Tumors. Because expression of the ATF2 peptide (constitutive, inducible, or via adenovirus delivery) was shown to efficiently inhibit the formation of SW1 as well as B16F10 tumors in vivo (17), we assessed whether administration of the peptide as a bacterially produced fusion protein would suffice to inhibit melanoma growth. To this end we chose to use the HIV-TAT system, given its ability to elicit potent delivery of its fusion proteins through cellular membranes (19) . Further, all of the ATF2 peptide constructs contain a fusion protein with penetratin, which resemble those of the HIV-TAT peptide (17) . Following its production in bacteria and purification on nickel beads ( Fig. 2A) , 1 g/mm 3 of the peptide was injected into 48 mm 3 -size SW1 tumors followed by a second injection at the indicated time points (Fig. 2B) ; thus, the amount of peptide injected was directly proportional to the size of the tumor. Before their injection into mice, tumor cells used in this study were infected with GFP, enabling follow-up observations of tumor size in real time without need of surgery. Using a UV lamp allowed monitoring changes in tumor mass, as shown in Fig. 2B . Whereas the control HIV-TAT construct had no effect on SW1 tumor growth, injection of the HIV-TAT-ATF2 51-100 fusion protein caused a marked decrease in tumor mass noticeable within a day or two after the first injection, and more so after 4 days (Fig. 2B) . These data provided the first evaluation of the effect of ATF2 peptide in vivo at different stages after its administration. Further analysis was carried out upon termination of the experiment, 13 days after the second injection. Of 20 tumors 9 were no longer visible after 3 days (2 tumors), 6 days (4 tumors), and 10 days (3 tumors) after the first injection of the HIV-TAT-ATF2 51-100 peptide. At the end of the experiment, 16 days after the first injection of the peptide, 11 of 20 tumors exhibited marked growth inhibition (Fig. 2C) .
Significantly, whereas the SW1 tumors injected with the control HIV-TAT peptide metastasized to the lungs to form multiple lesions, such tumors were no longer seen in any animal that received the HIV-TAT-ATF2 51-100 peptide (Fig. 3A) . Microscopic examination using H&E staining confirmed the presence of multiple metastatic lesions within the lungs of control animals but not in the ATF2 peptide-expressing group (Fig. 3B) . Lung metastases were substantially more pronounced upon visualization of GFP under a fluorescence microscope, which enabled detection of GFP-positive lesions (Fig. 3C ). These findings confirm that the GFP-expressing SW1 cells are those that metastasized to generate these lesions. Significantly, no such lesions were found in animals into which the HIV-TAT-ATF2 51-100 peptide had been injected (Fig. 3C) . Together, these data suggest that administration of the ATF2 51-100 peptide as a HIV-TAT fusion peptide into tumors results in efficient inhibition of tumorigen- was carried out with NH 2 -terminal ATF2 antibodies. B. SW1 cells that stably express GFP were injected s.c. into C3H mice. When a tumor reached the size of 48 mm 3 , control (HIV-TAT) or HIV-TAT-ATF2 51-100 peptide was injected into multiple sites within it. Tumor size was assessed with UV light illumination at the indicated time points. C. Data obtained from a group of 18 animals studied over the indicated period reflecting changes in the growth of SW1 tumors (P Ͻ 0.003; t-test). Arrows point to the time of peptide injection. *, cases where tumor was no longer seen (* ϭ one animal). Bars, ϮSD. Amino-Acids 51 to 60 of ATF2 Elicit Efficient Inhibition of Melanoma Growth in Vivo. Our recent studies with 50aa of ATF2 highlighted the importance of JNK in mediating spontaneous apoptosis of melanoma cells (18) . Mutation within the JNK association domain on ATF2 rendered the peptide inactive, as it no longer could alter transcriptional activities from TRE and Jun2-based sequences, nor could it sensitize melanomas to apoptosis or inhibit their growth in vivo (18) . These observations led us to explore the possible role of a smaller peptide that would contain the intact JNK binding site. To this end we generated 3 peptides of differing sizes (aa 51 to 80; aa 51 to 70; and aa 51 to 60) and compared their ability to inhibit tumor growth of SW1 cells in vivo. RT-PCR reactions confirmed the expression of the peptide's transcripts in the SW1 cells (Fig. 4A) . Subcutaneous injection of 10 6 SW1 cells expressing the control construct resulted in formation of 1,100-mm 3 size tumors within 18 days. However, expression of the 50aa peptide in these cells (constitutive expression based on selection of drug-resistant cells) decreased tumor size to 300 mm 3 , a result that resembled the degree of inhibition in previous studies (17) . Strikingly, constitutive expression of each of the 3 shorter peptides also elicited inhibition of melanoma growth that varied from 400 to 600 mm 3 (Fig. 4B ). Both the 20aa and 10aa peptides, spanning aa 51 to 60 and aa 51 to 70, respectively, elicited efficient inhibition close to that observed with the 50aa peptide. These data suggest that the 51 to 60aa peptide harbors the critical domain required for inhibition of SW1 growth in vivo. Given our intention to minimize the size of the peptide, additional evaluation was performed on the 10aa peptide. ATF2 51-60 Peptide Increases TRE-Based Transcriptional Activities and Sensitizes Melanoma Cells to Basal Apoptosis. We next assessed changes in transcriptional activities mediated by ATF2 and its heterodimeric partners, using the TRE and Jun2 promoter sequences linked to the Luciferase marker gene. Expression of ATF2 51-100 had been shown to elicit marked increase in the degree of TRE-Luc activities (ref. 17 ; also confirmed in Fig. 5A) . Similarly, expression of ATF2 51-60 was also efficient in increasing TRE-Luc activities (Fig. 5A) . These findings suggest that the short peptide elicits similar changes in promoters containing TRE sequences. In contrast, transcriptional activities from Jun2-Luc, which was efficiently inhibited upon expression of ATF2 51-100 (ref. 17 ; Fig. 5B ), were no longer inhibited but slightly elevated in response to expression of the 51 to 60aa peptide. This suggests that inhibition of ATF2 transcriptional activities via the 50aa peptide could no longer be mediated in response to expression of the shorter peptide. These findings suggest that the 10aa peptide affects primarily the Jun/JNK signaling cascade via altered TRE-dependent activities.
Expression of ATF2 51-60 Induces Spontaneous Apoptosis of Melanoma Cells. We next assessed the degree of apoptosis in SW1 cells under normal growth (spontaneous) as well as after treatment with chemotherapeutic drugs. Normally, SW1 cells are highly resistant to apoptosis after various treatments (16, 17) . Such resistance was reduced upon expression of the ATF2 51-60 peptide, because treatment with the protein kinase inhibitor UCN-01 (shown as representative of various treatments) induced an increase (20 to 40%) in apoptosis (Fig.  5C) . However, the degree of UCN-01-induced apoptosis was substantially higher in melanoma cells that express the 50aa peptide (20 to 77%; Fig. 5C ). This observation suggests that the 10aa peptide is less efficient in sensitization of melanoma cells to apoptosis after treatment.
However, SW1 cells that express the shorter peptide underwent spontaneous apoptosis, which was seen in the absence of treatment (12 to 37%; f, third panel, Fig. 5C ). Induction of basal apoptosis was also seen, at somewhat higher levels, upon expression of the ATF2 51-100 peptide (12 to 55%; f, second panel, Fig. 5C ). These (10 6 ) were injected s.c. into CH3 mice, and tumor growth was monitored for 18 days, at which point tumors were removed and their size carefully assessed. Each group included 6 animals, and each experiment was performed twice (P Ͻ 0.01; t test). Bars, ϮSD.
Fig. 5. Expression of ATF2
51-60 increases TRE-Luc but not Jun2-Luc activities and induces spontaneous apoptosis of SW1 melanoma cells. SW1 cells, which constitutively express the ATF2 peptides indicated in the figure, were transfected with either TRE-Luc (A) or with Jun2-Luc (B), and proteins were prepared for analysis of luciferase activity after 18 hours. Analysis was performed in duplicate, and the data reflect 3 independent experiments. C. SW1 cells that express the peptide were analyzed to establish the degree of spontaneous (basal) apoptosis as well as apoptosis 24 hours after treatment with the chemotherapeutic drug UCN-01. The data represent triplicate analysis reproduced 3 times. Bars, ϮSD.
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on May 28, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from findings suggest that whereas sensitization by the full-length peptide (aa 51 to 100) is mediated via two distinct mechanisms-spontaneous and inducible apoptosis-the shorter peptide 51-60 primarily elicits spontaneous, and is less efficient in inducing, apoptosis in response to treatment.
The ATF2 Peptides Activate Caspase 9 and Causes PARP Cleavage. To assess which of the proapoptotic components is affected upon expression of ATF2 peptides, we have analyzed possible changes in the profile of caspases. As shown in Fig. 6 , treatment of both human and mouse melanoma cells with UCN-01 caused activation of caspase 9, as reflected by the formation of the corresponding cleavage fragments. Cells that express either the 10 or 50aa peptides revealed activation of caspase 9 even before treatment with UCN-01. Treatment with UCN-01 retained the same level of caspase 9 cleavage as seen before treatment (Fig. 6 ). These data indicate that the expression of the ATF2 peptides is sufficient for the activation of caspase 9, which could explain, in part, how expression of these peptide causes spontaneous apoptosis. Similarly, PARP cleavage was observed upon treatment of the control cells, but also in cells that express ATF2 peptides, before their exposure to UCN-01 (Fig. 6) . Indeed, caspase 3, which is responsible for PARP cleavage, was also activated on expression of the ATF2 peptides (data not shown). These data suggests that both peptides suffice to induce caspase and PARP cleavage, which reflects cell commitment for apoptosis.
The ATF2 51-60 Peptide Increases the Association of JNK with c-Jun. The ability of the short peptide to elicit major changes in TRE-dependent transcription and spontaneous apoptosis led us to assess possible changes in the JNK-Jun association. The 51 to 100aa peptide binds to JNK, resulting in increased basal JNK activity (18) and thereby explaining the increase in the stability and activity of c-Jun upon expression of this peptide (17, 18) . Similarly, the short peptide increases the in vitro association between JNK and c-Jun in a dose-dependent manner, also resulting in increased Jun transcriptional activities (Fig. 7, A-C) . Such an effect was not observed in JNK-ATF2 association (Fig. 7, A-C) . This finding indicates that the ATF2 51-60 peptide efficiently increases the affinity of JNK for c-Jun, enabling greater phosphorylation and activation, which coincide with higher stability. Along these lines, mutation within the JNK binding region of the 50aa peptide markedly reduced its ability to inhibit tumorigenicity (18) .
Gene Expression Profiling of SW1 Tumors Expressing the ATF2
51-100 Peptide. To elucidate the molecular pathways affected by expression of the ATF2 51-100 peptide, we used cDNA microarray analysis to compare the RNA expression profiles of SW1 tumors that express this peptide or a control vector (Fig. 8A) . The mRNA was prepared from a pool of four tumors obtained from two different experiments. In both cases tumors were excised 2 weeks after subcutaneous injection of cells. Because the fluorescently labeled Cy dyes may incorporate into the reverse-transcribed cDNA with different efficiencies, RNA isolated from both cell types was always labeled with both combinations of Cy dyes. Genes either up-or downregulated by Ͼ2.5-fold were identified on the basis of a scatter plot analysis (Fig. 8A) . SW1 vector control cells were labeled with Cy-3 (F532), and the SW1-ATF2 51 to 100 peptide-expressing cells were labeled with Cy-5 (F635). Genes up-regulated in response to the expression of the ATF2 51-100 peptide appear red on the microarray, whereas genes down-regulated in tumors expressing the peptide (compared with control tumors) appear green (Fig. 8A) . Clustering analysis of the array data revealed several interesting patterns of gene expression. A large group of tumor necrosis factor-related genes were strongly up-regulated in tumors that express the ATF2 51-100 peptide (Fig. 8B) .
In addition, tumor suppressor genes and tumor rejection antigens were clustered within this group. Of interest, and in accordance with 51-100 peptide. Tumors generated in the absence or presence of this peptide were used as source of mRNA for array analysis of 10k mouse genes (see Materials and Methods for details). A depicts the overall distribution of the genes found to exhibit altered expression, whereas B provides a list of genes that were found to be induced or repressed on expression of the ATF2 peptide. In all of the cases, the data represent analyses carried out four times from four different pools of tumors.
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Research. (Fig. 8B) . Down-regulation of Fas-associated genes would result in reduced apoptosis via the Fas pathway and explain why there was no change in the growth and development of these tumors in GLD mice, which are deficient in Fas ligand (ref. 17 ; data not shown). Concomitant with decrease in Fas-associated genes was up-regulation of tumor necrosis factor-related transcripts, which constitutes the other major apoptosis cascade. These changes reveal that expression of the ATF2 peptide efficiently altered the balance of apoptosis cascades from Fas toward the tumor necrosis factor pathway, which otherwise provides a promitogenic signal in late stage melanomas (20) . Interestingly, we also observed a consistent down-regulation of growth-associated genes including epidermal growth factor, hepatoma-derived growth factor, and insulin-like growth factor, and several interferon-associated genes (Fig. 8B) .
Among other up-regulated transcripts (Table 1A) Among the additional transcripts down-regulated in ATF2-expressing tumors (Table 1B) NOTE. Shown is extended list of genes that were found to be modified based on gene profiling analysis described in Fig. 8 .
Research. IFN-␤; ref. 33) . This panel provides important mechanistic insights with regard to changes in the expression pattern of genes that occurred in vivo in the course of inhibiting tumor growth in response to expression of the ATF2 51-100 peptide.
DISCUSSION
The study presented here demonstrates the ability of a short peptide derived from the ATF2-transactivating domain to alter melanoma growth and metastasis capacity in vivo with 2 different model systems and 2 different modes of expression. The efficiency of the ATF2 51-100 peptide seems to be dependent on the characteristics of the tumor to which it is targeted. Whereas injection of the HIV-TAT-ATF2 peptide resulted in a complete regression in some of the SW1 tumors, the effect on the two human tumors tested was limited and was better observed on additional treatment with chemotherapeutic or pharmacological inhibitors. The difference among tumors could be attributed to differences in genetic and epigenetic background of the tumor and its host. Changes in the effectiveness of the ATF2 peptide could be also attributed to alteration of the immune response, either by the tumorigenicity of the different tumors or by changes elicited by the peptide that may trigger better immune recognition. The use of immunologically impaired nude mice for the analysis of the human tumors may also explain the nature of the differences seen in the effectiveness of the ATF2 peptide between the human and mouse tumor models.
The sensitization of human melanomas to treatment by either the pharmacological inhibitor of p38 or by the chemotherapeutic drug UCN-01 points to an important advance in treatment of these tumors by reagents that otherwise do not affect this tumor type. Such sensitization can be attributed to changes in apoptotic cascade (switch toward the tumor necrosis factor-related apoptosis-inducing ligand pathway; 17) combined with decreased NF-B antiapoptotic activities 4 and the activation of caspase 9 and caspase 3, based on the cleavage of PARP. Significantly, both caspase activation and PARP cleavage were seen on expression of the ATF2 peptides, thereby substantiating their ability to induce spontaneous apoptosis without additional treatment. It is important to emphasize that our studies in the SW1 and B16F10 tumor settings were limited to the effect of the peptide alone as it was sufficient to elicit striking inhibition of these aggressive tumors. It is expected that the effects of the ATF2 peptide on tumor growth rate and metastasis would be improved by combining the peptide with other treatments, including inhibitors of stress kinases, immunologic modulators, or chemotherapeutic drugs.
The present study extends the finding that the ATF2 51-100 peptide is capable of inhibiting melanoma growth and metastasis. Here we show that administration of the 50aa peptide as a fusion protein with HIV-TAT is sufficient to cause marked inhibition of the SW1 tumors, even to the point of their complete regression, while eliminating metastases commonly produced by tumors of this type.
Because of reduced ATF2 and elevated transcriptional activities of Jun family members, a large subset of genes regulated by ATF2 and c-Jun were found to exhibit altered expression-as shown here for elevated tumor necrosis factor-related genes and down-regulation of growth-associated and IFN-related genes, as revealed by the gene profiling analysis.
We additionally show that administration of a 10aa peptide that encompasses the JNK binding site sensitizes melanoma to spontaneous apoptosis in vitro and inhibits tumor formation in vivo. The short peptide preserves some of the activities characterized previously for the 51 to 100aa peptide, because it affects TRE-but not Jun-2-dependent transcription. As a result, tumors expressing this peptide are prone to undergo spontaneous apoptosis in the absence of external drugs or treatment. This sensitization is attributed to the change in TRE-mediated transcription, which is dependent on JNK-Jun and JunD (18) . The ability of the shorter peptide to alter TRE-dependent transcription is attributed to the ability of the peptide to increase JNK binding with its substrate, c-Jun. The greater association may have an impact on phosphorylation in trans of JunD (34) , as well as possible effects on other transcriptional regulators of Jun, including HDAC3, the repression of which Jun transcription depends on its phosphorylation by JNK (35) .
Equally intriguing is the finding that the shorter peptide did not affect Jun2 transcription, which coincides with the lower level of apoptosis induced upon treatment of cells that express the longer form of this peptide with chemotherapeutic drugs. This observation further highlights distinct mechanisms required for basal apoptosis versus those necessary for inducible apoptosis. Our findings also reveal the importance of basal apoptosis for inhibition of tumorigenicity of melanoma. Expression of the short peptide suffices for induction of spontaneous apoptosis and inhibition of melanoma growth in vivo. These observations are consistent with our earlier studies, which revealed that such inhibition is mediated in part by abundant apoptosis found in tumors expressing the ATF2 peptide (18) . These data, together with the ability of the HIV-TAT-ATF2 51-100 peptide to inhibit melanoma growth and metastasis, points to the possible use of these reagents for novel drug design in melanoma and possibly other tumor types.
